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This editorial refers to manuscript “Pitfalls in the measurement of muscle mass: a need for a reference standard” published by Buckinx et al. in Journal of Cachexia,
Sarcopenia and Muscle 2018; 9: 269–278.
Sarcopenia as a clinical term was suggested in 1988 by Irwin
Rosenberg to refer an age-dependent skeletal muscle
wasting.1 In recent years, sarcopenia became more and more
relevant in clinical practice. Beside the progressively aging
population in our society, an increasing number of patients
suffering from chronical diseases contributes to the growing
prevalence of sarcopenia. Indeed, muscle wasting has been
found in association with several diseases such as chronic
heart failure,2 chronic kidney disease,3 chronic obstructive
pulmonary disease (COPD),4 cancer,5 rheumatoid arthritis,6
diabetes mellitus,7 peripheral arterial disease8 etc. The
consequences of decreasing muscle mass are wide-ranging
including metabolic dysregulation with insulin resistance
and dyslipidemia, diminished bone mineral content, muscle
structural changes with reduction of the neuromuscular
junctions and muscle ﬁbres switch, decrease of the ﬁtness
level up to frailty with increase in falls and functional disabil-
ity.9 Muscle mass could be measured by several methods and
mostly special technical equipment is required.
The recent publication “Pitfalls in the measurement of
muscle mass: a need for a reference standard” by Buckinx
et al. in Journal of Cachexia, Sarcopenia and Muscle (JCSM)
investigated currently used methods for measurements of
the lean body mass and muscle mass in order to determine
a standard technique for use by clinicians and researchers.10
Therefore, members of the European Society for Clinical
and Economic Aspects of Osteoporosis and Osteoarthritis
working group performed a literature search between
2000 and 2016 on the role and methods of muscle mass
measurements and the main recommendations were sum-
marized in this publication. The methods of muscle mass
assessments applied in multiple studies were compared for
several key criteria such as safety, accuracy, feasibility, cost
and availability. The main conclusion of this publication was
to consider Dual X-Ray Absorptiometry (DXA) as a ‘reference
standard’ for assessment of the muscle mass. Other
techniques including computed tomography, magnetic
resonance imaging, bioelectrical impedance analysis (BIA),
ultrasound, biomarkers, or anthropometric measures used
for muscle mass assessments, all have a number of various
considerations accounting for their limited applicability in
clinical practice. Every technique has its advantages and
limitations in different settings of clinical and scientiﬁc
application and hence it is challenging to deﬁne a ‘gold
standard’ for muscle mass measurements.
Yet, a question is to what extent are precise measurements
of the muscle mass necessary to make a clinical diagnosis of
sarcopenia? Indeed, a dominating role of the muscle function
and muscle strength rather than muscle bulk in the diagnos-
ing of sarcopenia has been proposed recently.11 Thus, several
deﬁnitions of sarcopenia include two diagnostic criteria: (a)
low muscle mass and (b) low muscle strength and/or muscle
function.12–15 Some of the consensus deﬁnitions even
suggest starting diagnosing of sarcopenia with assessment
of the muscle function or muscle strength and complete it
by measurements of the muscle mass.12,13 Thus, the Health,
Aging and Body Composition (Health ABC) Study investigating
2,292 participants showed a high impact of quadriceps and
handgrip strength on mortality while lean mass as assessed
by DXA was not associated with mortality.16 The recent study
by Locquet et al. comparing ﬁve screening methods for
sarcopenia and investigating about 300 participants over
two years, showed that the best results for identifying
sarcopenic individuals were achieved if screening was
performed with assessment of handgrip strength (a robust
measure of muscle function), age and calf circumference (a
surrogate of muscle bulk).17 Another study investigating 106
older patients with advanced cancer showed a positive
association between muscle strength and overall survival at
the beginning of chemotherapy.18 Clearly, muscle strength is
the most relevant marker of muscle quality.16,19 In contrast,
muscle mass does not ultimately mean a good muscle
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function. Thus, a recent study investigating 140 adults over
65 years of age showed normal muscle volume and reduced
handgrip strength in 13% of participants, mainly older
females.20 In turn, in several interventional clinical trials
increased muscle bulk was reported but this was not
accompanied by signiﬁcant increase in muscle functional
capacity, rendering the respective therapeutic approach
futile. Of course the role of muscle tissue as the body’s main
protein reservoir needs to be taken into account as appropri-
ate and readily adaptive protein turnover is vital in multiple
metabolic (anabolic capacity) and immune response pro-
cesses (immune globulin synthesis). An age-related reduction
of muscle strength has been termed dynapenia.21 At tissue,
cellular and molecular levels, sarcopenia-related changes of
skeletal muscle are similar to those in dynapenia: decline of
the protein synthesis, increased oxidative stress, inﬂamma-
tion, alterations in the neuromuscular junctions or neuro-
transmitters, metabolic changes.21,12,22–24 However, only a
combination of techniques applied for the muscle mass
measurements may provide both information on the muscle
mass and muscle quality.
Measurement of handgrip strength and gait speed are well
established in clinical practice. However, a discrepancy of
reference values is present between various deﬁnitions of
sarcopenia. Thus, cutoff values for the handgrip strength
range between less than 16 to 20 kg for women and between
26 to 30 kg for men.14,12 This applies also to the gait speed
with values less than 0.8 to 1.0 m/s and short physical perfor-
mance battery (SPPB) with less than 8 to 9 points as a refer-
ence for the low muscle strength.13,15,25 Consequently, the
reported prevalence of sarcopenia is wide-ranging. Thus, a
study investigating over 3,000 elderly women participating
in the EPIDémiologie de l’OStéoporose study revealed a
sarcopenia prevalence ranging between 3.3% and 20% de-
pending on one of the six used deﬁnitions.26,27 A recent
meta-analysis investigating over 58,000 individuals older than
60 years worldwide, reported a prevalence of sarcopenia
ranging between 6% and 19% depending on sex, method of
muscle mass assessment and geographic distribution.28 This
meta-analysis was based on three of the seven operational
sarcopenia consensus deﬁnitions.29 Moreover, a prevalence
of disease-associated sarcopenia varies across clinical trials.
For instance, in chronic heart failure a prevalence between
19.5% and 68%2,30 and in COPD between 15% and 25%31,32
has been described. Thus, a high prevalence of sarcopenia
in clinical trials and registries is a common observation
that requires better recognition as a relevant complication
or comorbidity with consequent appreciation in compre-
hensive and holistic treatment concepts.
Nevertheless, sarcopenia is reversible. A recent observa-
tional study investigating 4,000 community-dwelling older
adults aged ≥65 years showed reversibility of sarcopenia in
20% and 14% of the patients at 2 and 4 years’ follow-up,
respectively.33 Factors associated with the reversibility of
sarcopenia were younger age, higher body mass index,
absence of impairment in performing of instrumental activi-
ties of daily living.34 Surprisingly, neither physical activity nor
protein level or vitamin D intake were associated with the
reversibility of sarcopenia in this study.34 Another study, in-
vestigating 30 patients with gastrointestinal stromal tumour
who were treated with imatinib, showed a reversibility of
sarcopenia in 60% of the patients.35 A reversibility of disuse
atrophy of type I and II muscle ﬁbres 24 weeks after re-use
has been recently shown in an experimental study.36 In
addition, resistance training is known to promote an
improvement of muscle strength, muscle mass, quality of
the muscle tissue, better physical performance and indepen-
dence.37,38 Therefore, recognizing sarcopenia by whatever
method best suited to a speciﬁc clinical setting is highly
relevant as it may impact on adequate treatment strategies
and eventually lead to reduced frailty and better outcome.
Conﬂict of interest
W.D. has received personal fees from Boehringer Ingelheim,
Bristol-Myers Squibb, Pﬁzer, Sphingotec, Vifor Pharma, and
ZS Pharma as well as research support from Sanoﬁ, Vifor
Pharma and ZS Pharma. We acknowledge support from the
German Research Foundation (DFG) and the Open Access
Publication Fund of Charité – Universitätsmedizin Berlin.
References
1. Rosenberg IH. Sarcopenia: origins and
clinical relevance. J Nutr 1997; 127:
990S–991S.
2. Fülster S, Tacke M, Sandek A, Ebner N,
Tschöpe C, Doehner W, Anker SD, von
Haehling S. Muscle wasting in patients
with chronic heart failure: results from
the studies investigating co-morbidities
aggravating heart failure (SICA-HF).
Eur Heart J 2013; 34: 512–519.
3. Patel SS, Molnar MZ, Tayek JA, Ix JH,
Noori N, Benner D, Heymsﬁeld S, Kopple
JD, Kovesdy CP, Kalantar-Zadeh K. Serum
creatinine as a marker of muscle mass in
chronic kidney disease: results of a
cross-sectional study and review of litera-
ture. J Cachexia Sarcopenia Muscle 2013;
4: 19–29.
4. Kneppers AEM, Langen RCJ, Gosker HR,
Verdijk LB, Cebron Lipovec N, Leermakers
PA, Kelders MCJM, de Theije CC, Omersa
D, Lainscak M, Schols AMWJ. Increased
Myogenic and Protein Turnover Signaling
in Skeletal Muscle of Chronic Obstructive
Pulmonary Disease Patients With Sarco-
penia. J Am Med Dir Assoc 2017; 18: 637.
5. Barkhudaryan A, Scherbakov N, Springer
J, Doehner W. Cardiac muscle wasting in
individuals with cancer cachexia. ESC
Heart Fail 2017; 4: 458–467.
742 Editorial
ESC Heart Failure 2018; 5: 741–744
DOI: 10.1002/ehf2.12356
6. Pineda-Juárez JA, Lozada-Mellado M,
Ogata-Medel M, Hinojosa-Azaola A,
Santillán-Díaz C, Llorente L, Orea-
Tejeda A, Alcocer-Varela J, Espinosa-Mo-
rales R, González-Contreras M, Castillo-
Martínez L. Body composition evaluated
by body mass index and bioelectrical im-
pedance vector analysis in women with
rheumatoid arthritis. Nutrition 2018;
53: 49–53.
7. Trierweiler H, Kisielewicz G, Hoffmann
Jonasson T, Rasmussen Petterle R,
Aguiar Moreira C, Zeghbi Cochenski
Borba V. Sarcopenia: a chronic complica-
tion of type 2 diabetes mellitus. Diabetol
Metab Syndr 2018; 10: 25.
8. Addison O, Prior SJ, Kundi R, Serra MC,
Katzel LI, Gardner AW, Ryan AS.
Sarcopenia in Peripheral Arterial Dis-
ease: Prevalence and Effect on Func-
tional Status. Arch Phys Med Rehabil
2018; 99: 623–628.
9. Janssen I, Heymsﬁeld SB, Ross R. Low
relative skeletal muscle mass
(sarcopenia) in older persons is associ-
ated with functional impairment and
physical disability. J Am Geriatr Soc
2002; 50: 889–896.
10. Buckinx F, Landi F, Cesari M, Fielding
RA, Visser M, Engelke K, Maggi S,
Dennison E, Al-Daghri NM, Allepaerts
S, Bauer J, Bautmans I, Brandi ML,
Bruyère O, Cederholm T, Cerreta F, Che-
rubini A, Cooper C, Cruz-Jentoft A, Mc-
Closkey E, Dawson-Hughes B, Kaufman
JM, Laslop A, Petermans J, Reginster
JY, Rizzoli R, Robinson S, Rolland Y,
Rueda R, Vellas B, Kanis JA. Pitfalls in
the measurement of muscle mass: a
need for a reference standard. J
Cachexia Sarcopenia Muscle 2018; 9:
269–278.
11. Cederholm T, Morley JE. Sarcopenia:
the new deﬁnitions. Curr Opin Clin Nutr
Metab Care 2015; 18: 1–4.
12. Chen LK, Liu LK, Woo J, Assantachai P,
Auyeung TW, Bahyah KS, Chou MY,
Chen LY, Hsu PS, Krairit O, Lee JS, Lee
WJ, Lee Y, Liang CK, Limpawattana P,
Lin CS, Peng LN, Satake S, Suzuki T,
Won CW, Wu CH, Wu SN, Zhang T, Zeng
P, Akishita M, Arai H. Sarcopenia in
Asia: consensus report of the Asian
Working Group for Sarcopenia. J Am
Med Dir Assoc 2014; 15: 95–101.
13. Fielding RA, Vellas B, Evans WJ, Bhasin
S, Morley JE, Newman AB, Abellan van
Kan G, Andrieu S, Bauer J, Breuille D,
Cederholm T, Chandler J, De Meynard
C, Donini L, Harris T, Kannt A, Keime
Guibert F, Onder G, Papanicolaou D,
Rolland Y, Rooks D, Sieber C, Souhami
E, Verlaan S, Zamboni M. Sarcopenia:
an undiagnosed condition in older
adults. Current consensus deﬁnition:
prevalence, etiology, and consequences.
International working group on
sarcopenia. J Am Med Dir Assoc 2011;
12: 249–256.
14. Cruz-Jentoft AJ, Baeyens JP, Bauer JM,
Boirie Y, Cederholm T, Landi F, Martin
FC, Michel JP, Rolland Y, Schneider
SM, Topinková E, Vandewoude M, Zam-
boni M, European Working Group on
Sarcopenia in Older People. Sarcopenia:
European consensus on deﬁnition
and diagnosis: Report of the European
Working Group on Sarcopenia in
Older People. Age Ageing 2010; 39:
412–423.
15. Morley JE, Abbatecola AM, Argiles JM,
Baracos V, Bauer J, Bhasin S, Cederholm
T, Coats AJ, Cummings SR, Evans WJ,
Fearon K, Ferrucci L, Fielding RA,
Guralnik JM, Harris TB, Inui A,
Kalantar-Zadeh K, Kirwan BA,
Mantovani G, Muscaritoli M, Newman
AB, Rossi-Fanelli F, Rosano GM,
Roubenoff R, Schambelan M, Sokol
GH, Storer TW, Vellas B, von Haehling
S, Yeh SS, Anker SD, Society on
Sarcopenia, Cachexia and Wasting Dis-
orders Trialist Workshop. Sarcopenia
with limited mobility: an international
consensus. J Am Med Dir Assoc 2011;
12: 403–409.
16. Newman AB, Kupelian V, Visser M,
Simonsick EM, Goodpaster BH,
Kritchevsky SB, Tylavsky FA, Rubin SM,
Harris TB. Strength, but not muscle
mass, is associated with mortality in
the health, aging and body composition
study cohort. J Gerontol A Biol Sci Med
Sci 2006; 61: 72–77.
17. Locquet M, Beaudart C, Reginster JY,
Petermans J, Bruyère O. Comparison of
the performance of ﬁve screening
methods for sarcopenia. Clin Epidemiol
2017; 10: 71–82.
18. Versteeg KS, Blauwhoff-Buskermolen S,
Buffart LM, de van der Schueren MAE,
Langius JAE, Verheul HMW, Maier AB,
Konings IR. Higher Muscle Strength Is
Associated with Prolonged Survival in
Older Patients with Advanced Cancer.
Oncologist 2018; 23: 580–585.
19. Goodpaster BH, Park SW, Harris TB,
Kritchevsky SB, Nevitt M, Schwartz AV,
Simonsick EM, Tylavsky FA, Visser M,
Newman AB. The loss of skeletal muscle
strength, mass, and quality in older
adults: the health, aging and body com-
position study. J Gerontol A Biol Sci Med
Sci 2006; 61: 1059–1064.
20. Chang KV, Wu WT, Huang KC, Jan WH,
Han DS. Limb muscle quality and quan-
tity in elderly adults with dynapenia
but not sarcopenia: An ultrasound imag-
ing study. Exp Gerontol 2018; 108:
54–61.
21. Clark BC, Manini TM.What is dynapenia?
Nutrition 2012; 28: 495–503.
22. Ebner N, Sliziuk V, Scherbakov N,
Sandek A. Muscle wasting in ageing
and chronic illness. ESC Heart Fail
2015; 2: 58–68.
23. Scherbakov N, Sandek A, Doehner W.
Stroke-related sarcopenia: speciﬁc char-
acteristics. J Am Med Dir Assoc 2015;
16: 272–276.
24. Schaap LA, Pluijm SM, Deeg DJ, Harris
TB, Kritchevsky SB, Newman AB, Col-
bert LH, Pahor M, Rubin SM, Tylavsky
FA, Visser M, Health ABC Study. Higher
inﬂammatory marker levels in older per-
sons: associations with 5-year change in
muscle mass and muscle strength. J
Gerontol A Biol Sci Med Sci 2009; 64:
1183–1189.
25. Studenski SA, Peters KW, Alley DE,
Cawthon PM, McLean RR, Harris TB,
Ferrucci L, Guralnik JM, Fragala MS,
Kenny AM, Kiel DP, Kritchevsky SB,
Shardell MD, Dam TT, Vassileva MT.
The FNIH sarcopenia project: rationale,
study description, conference recom-
mendations, and ﬁnal estimates. J
Gerontol A Biol Sci Med Sci 2014; 69:
547–558.
26. Dupuy C, Lauwers-Cances V, Guyonnet
S, Gentil C, Abellan Van Kan G,
Beauchet O, Schott AM, Vellas B, Rol-
land Y. Searching for a relevant deﬁni-
tion of sarcopenia: results from the
cross-sectional EPIDOS study. J Cachexia
Sarcopenia Muscle 2015; 6: 144–154.
27. Scherbakov N, Doehner W. Searching for
a relevant deﬁnition of sarcopenia: re-
sults from the cross-sectional EPIDOS
study. J Cachexia Sarcopenia Muscle
2016; 7: 100–101.
28. Shaﬁee G, Keshtkar A, Soltani A, Ahadi
Z, Larijani B, Heshmat R. Prevalence of
sarcopenia in the world: a systematic re-
view and meta- analysis of general pop-
ulation studies. J Diabetes Metab Disord
2017; 16: 21.
29. Bischoff-Ferrari HA, Orav JE, Kanis JA,
Rizzoli R, Schlögl M, Staehelin HB,
Willett WC, Dawson-Hughes B. Com-
parative performance of current deﬁni-
tions of sarcopenia against the
prospective incidence of falls among
community-dwelling seniors age 65
and older. Osteoporos Int 2015; 26:
2793–2802.
30. Pasini E, Aquilani R, Gheorghiade M,
Dioguardi FS. Malnutrition, muscle
wasting and cachexia in chronic heart
failure: the nutritional approach. Ital
Heart J 2003; 4: 232–235.
31. Jones SE, Maddocks M, Kon SS,
Canavan JL, Nolan CM, Clark AL, Polkey
MI, Man WD. Sarcopenia in COPD: prev-
alence, clinical correlates and response
to pulmonary rehabilitation. Thorax
2015; 70: 213–218.
32. Byun MK, Cho EN, Chang J, Ahn CM,
Kim HJ. Sarcopenia correlates with
systemic inﬂammation in COPD. Int J
Chron Obstruct Pulmon Dis 2017; 12:
669–675.
33. Yu R, Wong M, Leung J, Lee J, Auyeung
TW, Woo J. Incidence, reversibility, risk
factors and the protective effect of high
body mass index against sarcopenia in
community-dwelling older Chinese
adults. Geriatr Gerontol Int 2014; 14:
15–28.
34. Lawton MP, Brody EM. Assessment of
older people: Self-maintaining and in-
strumental activities of daily living.
Gerontologist 1969; 9: 179–186.
35. Moryoussef F, Dhooge M, Volet J, Barbe
C, Brezault C, Hoeffel C, Coriat R,
Bouché O. Reversible sarcopenia in
Editorial 743
ESC Heart Failure 2018; 5: 741–744
DOI: 10.1002/ehf2.12356
patients with gastrointestinal stromal
tumor treated with imatinib. J Cachexia
Sarcopenia Muscle 2015; 6: 343–350.
36. Fabis J, Danilewicz M, Zwierzchowski
JT, Niedzielski K. Atrophy of type I and
II muscle ﬁbers is reversible in the case
of grade >2 fatty degeneration of the
supraspinatus muscle: an experimental
study in rabbits. J Shoulder Elbow Surg
2016; 25: 487–492.
37. Westcott WL. Resistance training is med-
icine: effects of strength training on
health. Curr Sports Med Rep 2012; 11:
209–216.
38. Cunha PM, Tomeleri CM, Nascimento
MAD, Nunes JP, Antunes M, Nabuco
HCG, Quadros Y, Cavalcante EF,
Mayhew JL, Sardinha LB, Cyrino ES. Im-
provement of cellular health indicators
and muscle quality in older women with
different resistance training volumes.
J Sports Sci 2018; https://doi.org/
10.1080/02640414.2018.1479103
744 Editorial
ESC Heart Failure 2018; 5: 741–744
DOI: 10.1002/ehf2.12356
